NBIX - Neurocrine Biosciences Non-GAAP EPS of -$0.51 revenue of $420.4M beats by $11.33M
2023-05-03 07:42:54 ET
- Neurocrine Biosciences press release ( NASDAQ: NBIX ): Q1 Non-GAAP EPS of -$0.51.
- Revenue of $420.4M (+35.4% Y/Y) beats by $11.33M .
-
First Quarter INGREZZA Net Product Sales Highlights:
- INGREZZA first quarter 2023 net product sales were $410 million and grew 36% compared vs. the first quarter 2022
- Record number of new patients received therapy during the first quarter of 2023
For further details see:
Neurocrine Biosciences Non-GAAP EPS of -$0.51, revenue of $420.4M beats by $11.33M